Recursion Pharmaceuticals, Inc.

NasdaqGS RXRX

Recursion Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.00

Recursion Pharmaceuticals, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.

Recursion Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.00, a 0.00% change year over year.
Recursion Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.00, a 0.00% change year over year.
Recursion Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.00.

Key data

Date	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)

NasdaqGS: RXRX

Recursion Pharmaceuticals, Inc.

CEO	Dr. Christopher C. Gibson Ph.D.
IPO Date	April 16, 2021
Location	United States
Headquarters	41 South Rio Grande Street
Employees	500
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Key trends

Past 5 years